Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Inhaled triple therapy in chronic obstructive pulmonary disease

Single-inhaler triple therapy has been proposed for patients with symptomatic, frequently exacerbating chronic obstructive pulmonary disease (COPD), with the main aim of reducing eosinophilic-driven exacerbations by the inhaled corticosteroid moiety.1 Findings from the TRIBUTE study2 showed a 15% overall reduction in exacerbations and no difference in pneumonia risk when comparing a triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium to a dual combination of indacaterol plus glycopyrronium in COPD.